{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T13:03:51Z","timestamp":1758632631986},"reference-count":27,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.therap.2016.02.005","type":"journal-article","created":{"date-parts":[[2016,3,18]],"date-time":"2016-03-18T10:32:21Z","timestamp":1458297141000},"page":"223-228","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["The contribution of pharmacogenetics to pharmacovigilance"],"prefix":"10.1016","volume":"71","author":[{"given":"Emmanuelle","family":"Bondon-Guitton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabien","family":"Despas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Becquemont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.therap.2016.02.005_bib0165","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/tpj.2013.10","article-title":"Association of UGT1A1*28\u00a0polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians","volume":"14","author":"Liu","year":"2014","journal-title":"Pharmacogenomics J"},{"issue":"19","key":"10.1016\/j.therap.2016.02.005_bib0170","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1200\/JCO.2005.05.5400","article-title":"The role of UGT1A1*28\u00a0polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer","volume":"24","author":"Toffoli","year":"2006","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.therap.2016.02.005_bib0175","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/00008571-199902000-00006","article-title":"The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations","volume":"9","author":"Collie-Duguid","year":"1999","journal-title":"Pharmacogenetics"},{"issue":"4","key":"10.1016\/j.therap.2016.02.005_bib0180","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/clpt.2013.4","article-title":"Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013\u00a0update","volume":"93","author":"Relling","year":"2013","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.therap.2016.02.005_bib0185","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1001\/jama.293.12.1485","article-title":"Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia","volume":"293","author":"Stanulla","year":"2005","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.therap.2016.02.005_bib0190","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2217\/pgs.10.147","article-title":"Practical recommendations for pharmacogenomics-based prescription: 2010\u00a0ESF-UB conference on pharmacogenetics and pharmacogenomics","volume":"12","author":"Becquemont","year":"2011","journal-title":"Pharmacogenomics"},{"issue":"11","key":"10.1016\/j.therap.2016.02.005_bib0195","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.2217\/pgs.13.116","article-title":"DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis","volume":"14","author":"Terrazzino","year":"2013","journal-title":"Pharmacogenomics"},{"issue":"16","key":"10.1016\/j.therap.2016.02.005_bib0200","first-page":"3402","article-title":"CYP2D6\u00a0catalyzes tamoxifen 4-hydroxylation in human liver","volume":"57","author":"Dehal","year":"1997","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.therap.2016.02.005_bib0205","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/tpj.2008.7","article-title":"The AmpliChip CYP450\u00a0test: cytochrome P450 2D6\u00a0genotype assessment and phenotype prediction","volume":"9","author":"Rebsamen","year":"2009","journal-title":"Pharmacogenomics J"},{"issue":"33","key":"10.1016\/j.therap.2016.02.005_bib0210","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1200\/JCO.2007.12.2705","article-title":"Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6\u00a0and CYP2C19\u00a0genotypes","volume":"25","author":"Schroth","year":"2007","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.therap.2016.02.005_bib0215","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1001\/jama.2009.1420","article-title":"Association between CYP2D6\u00a0polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen","volume":"302","author":"Schroth","year":"2009","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.therap.2016.02.005_bib0220","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/jnci\/djs125","article-title":"CYP2D6\u00a0genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98\u00a0trial","volume":"104","author":"Regan","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.therap.2016.02.005_bib0225","series-title":"Systematic reviews on selected pharmacogenetic tests for cancer treatment: CYP2D6\u00a0for tamoxifen in breast cancer, KRAS for anti-EGFR antibodies in colorectal cancer, and BCR-ABL1\u00a0for tyrosine kinase inhibitors in chronic myeloid leukemia","author":"Terasawa","year":"2010"},{"issue":"2","key":"10.1016\/j.therap.2016.02.005_bib0230","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/clpt.2013.186","article-title":"CYP2D6\u00a0genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations","volume":"95","author":"Province","year":"2014","journal-title":"Clin Pharmacol Ther"},{"issue":"16","key":"10.1016\/j.therap.2016.02.005_bib0235","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1161\/CIRCULATIONAHA.112.100628","article-title":"Warfarin pharmacogenetics: a rising tide for its clinical value","volume":"125","author":"Johnson","year":"2012","journal-title":"Circulation"},{"issue":"13","key":"10.1016\/j.therap.2016.02.005_bib0240","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/archinte.167.13.1414","article-title":"Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action","volume":"167","author":"Wysowski","year":"2007","journal-title":"Arch Intern Med"},{"issue":"3","key":"10.1016\/j.therap.2016.02.005_bib0245","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3121\/cmr.3.3.137","article-title":"A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9\u00a0genotype and clinical data","volume":"3","author":"Hillman","year":"2005","journal-title":"Clin Med Res"},{"issue":"4","key":"10.1016\/j.therap.2016.02.005_bib0250","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1182\/blood-2008-04-149070","article-title":"The largest prospective warfarin-treated cohort supports genetic forecasting","volume":"113","author":"Wadelius","year":"2009","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.therap.2016.02.005_bib0255","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/humu.20731","article-title":"PharmGKB and the International Warfarin Pharmacogenetics Consortium: the changing role for pharmacogenomic databases and single-drug pharmacogenetics","volume":"29","author":"Owen","year":"2008","journal-title":"Hum Mutat"},{"issue":"8","key":"10.1016\/j.therap.2016.02.005_bib0260","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa0809329","article-title":"Estimation of the warfarin dose with clinical and pharmacogenetic data","volume":"360","author":"International Warfarin Pharmacogenetics Consortium","year":"2009","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.therap.2016.02.005_bib0265","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1056\/NEJMoa0708078","article-title":"Genetic determinants of response to warfarin during initial anticoagulation","volume":"358","author":"Schwarz","year":"2008","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.therap.2016.02.005_bib0270","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1161\/CIRCULATIONAHA.111.070920","article-title":"A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II)","volume":"125","author":"Anderson","year":"2012","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.therap.2016.02.005_bib0275","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMoa0808227","article-title":"Genetic determinants of response to clopidogrel and cardiovascular events","volume":"360","author":"Simon","year":"2009","journal-title":"N Engl J Med"},{"issue":"9660","key":"10.1016\/j.therap.2016.02.005_bib0295","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(08)61845-0","article-title":"Cytochrome P450 2C19\u00a0polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study","volume":"373","author":"Collet","year":"2009","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.therap.2016.02.005_bib0300","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1001\/jama.2011.1529","article-title":"Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis","volume":"306","author":"Cayla","year":"2011","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.therap.2016.02.005_bib0305","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2217\/pgs.10.38","article-title":"HLA: a pharmacogenomics success story","volume":"11","author":"Becquemont","year":"2010","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.therap.2016.02.005_bib0310","series-title":"Test compagnon associ\u00e9 \u00e0 une th\u00e9rapie cibl\u00e9e\u00a0: d\u00e9finitions et m\u00e9thode d\u2019\u00e9valuation","year":"2014"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716000238?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716000238?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T07:52:07Z","timestamp":1554277927000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595716000238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S0040595716000238"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2016.02.005","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The contribution of pharmacogenetics to pharmacovigilance","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2016.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2016.02.004","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS All rights reserved.","name":"copyright","label":"Copyright"}]}}